 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LYT-210 / PureTech
[VIRTUAL] Efficacy and characterization of a specific and potent monoclonal antibody, LYT-210, against immunosuppressive gd1 T cell in cancer () - Mar 11, 2021 - Abstract #AACR2021AACR_3278;
We have developed a novel, therapeutic immuno-oncology strategy specifically targeting imunosuppressive γδ1cells. Our data support that this therapeutic approach may have the potential to be transformative for the treatment of cancers where γδ1T cells drive a pro-tumorigenic, immunosuppressive environment.